NGM’s NGM621 now looks like a dead end, but there are plenty of others hoping for a piece of this market, including Roche and Lineage.
But data from Gather2 do not look as impressive as earlier results.
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.
Allergan's wet AMD candidate abicipar has apparently succeeded in phase III – but a safety signal could make it hard to compete against Regeneron's Eylea.